好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Pathway for Evaluation and Management of Anti-NMDA Receptor Encephalitis During Pregnancy
Autoimmune Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
9-007

To report a case and propose a potential pathway for evaluation and management of anti-NMDAR encephalitis in pregnancy. 

Anti-NMDA encephalitis during pregnancy is challenging for neurologists and requires multi-interdisciplinary care. Anti-NMDA receptor encephalitis is associated with behavioral disturbances including psychosis and seizures. Obstacles arise when evaluating and treating these patients including choosing imaging modalities, use of contrast, and interventions. Though there are published reports of anti-NMDAR encephalitis in pregnancy, we propose a potential pathway for evaluation and management in this patient population. 

Case report and literature review. 

A 19-year-old female with a history of unspecified seizure disorder and 15 weeks pregnant presented with subacute behavioral changes including psychosis and catatonia. Urine toxicology was negative. MRI brain was unremarkable. CSF findings were only significant for oligoclonal bands. Thirteen days after hospitalization, NMDAR antibody was positive in the CSF while negative in the serum. Abdominal ultrasound and MRI abdomen/pelvis were negative for an ovarian teratoma. She was started on plasma exchange prior to knowledge of positive CSF NMDAR antibody due to high clinical suspicion. Once the diagnosis was made, the patient was started on high dose intravenous methyl-prednisolone with improvement in symptoms. 

When assessing for an ovarian teratoma during pregnancy, we propose first to evaluate with an ultrasound, followed by an MRI of the abdomen/pelvis without contrast if negative. All first line agents (intravenous methyl-prednisolone, intravenous immunoglobulin, and plasma exchange) are safe during pregnancy. However, patient factors should be accounted for when choosing a first line-agent as well as anti-seizure medications. If needed, second line immunotherapy (e.g. Rituximab) also requires risk stratification due to uncertainty of developmental outcomes. More research is still needed on optimal management. It is important to take into account the safety profiles of imaging modalities and interventions prior to initiation in this patient population. 
Authors/Disclosures
Diana Ontiveros, MD
PRESENTER
Dr. Ontiveros has nothing to disclose.
James P. Ho, MD (UNC) Dr. Ho has nothing to disclose.
Dena Williams, DO Dr. Williams has nothing to disclose.